Company profile: Pardes Bio
1.1 - Company Overview
Company description
- Provider of direct-acting antivirals for the treatment of coronavirus, applying modern reversible-covalent chemistry to discover and develop novel oral drug candidates starting with COVID-19, as a clinical-stage biopharmaceutical company focused on improving patient access to these medicines.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pardes Bio
Cerus
HQ: United States
Website
- Description: Provider of blood safety pathogen reduction systems: INTERCEPT Blood System for Platelets and Plasma (available globally with regulatory approvals); INTERCEPT Red Blood Cell System (under regulatory review in Europe and in late-stage clinical development in the US); INTERCEPT Blood System of Cryoprecipitation to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex to treat and control bleeding associated with fibrinogen deficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus company profile →
Spring Bank Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule nucleic acid hybrid-based therapeutics and immuno-oncology candidates, including FS118, a LAG-3/PD-L1 mAb2 bispecific antibody in Phase 2 for head and neck cancer, NSCLC and DLBCL; FS120, an OX40/CD137 dual agonist mAb2 in Phase 1; FS222, a CD137/PD-L1 mAb2 in Phase 1 for PD-L1-low tumors; and SB 11285, an IV second-generation STING agonist in Phase 1, alone and with atezolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spring Bank Pharmaceuticals company profile →
Durata Therapeutics
HQ: United States
Website
- Description: Provider of late-stage clinical development of novel antibiotics for infectious diseases, focused on Vicuron’s antibiotic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durata Therapeutics company profile →
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
Clever Culture Systems
HQ: Switzerland
Website
- Description: Provider of intelligent image analysis solutions using artificial intelligence, including APAS Independence for automated microbial environmental monitoring with digital records, audit trails, standardized workflows and reduced human error, and MRSA and VRE Analysis Modules that automate detection on chromogenic media for efficient infection control by reporting negatives and triaging positives for review.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clever Culture Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pardes Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pardes Bio
2.2 - Growth funds investing in similar companies to Pardes Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pardes Bio
4.2 - Public trading comparable groups for Pardes Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →